Gena Wang
Stock Analyst at Barclays
(3.23)
# 1,068
Out of 5,143 analysts
241
Total ratings
44.94%
Success rate
2.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $19.50 | +310.26% | 8 | Feb 4, 2026 | |
| CYTK Cytokinetics | Assumes: Overweight | $87 | $70.10 | +24.11% | 6 | Jan 28, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $22.75 | +119.78% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $10.07 | +227.71% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $50.52 | -50.51% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $13.58 | +3.09% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.47 | +111.64% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $68.98 | -1.42% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $18.84 | +6.16% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $487.43 | -15.06% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $6.18 | +45.63% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $7.61 | +18.27% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $332.85 | +58.33% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $85.45 | +11.18% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $62.62 | +27.75% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.98 | +101.01% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $27.98 | -39.24% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $8.08 | +357.92% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $59 → $62 | $72.75 | -14.78% | 4 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $56.77 | -1.36% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $32.29 | -34.96% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $9.49 | +226.66% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.11 | +42.18% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $23.63 | -61.91% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $8.18 | +205.62% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.70 | +133.77% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $7.49 | +20.16% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.40 | +4,992.59% | 1 | Jan 6, 2017 |
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $19.50
Upside: +310.26%
Cytokinetics
Jan 28, 2026
Assumes: Overweight
Price Target: $87
Current: $70.10
Upside: +24.11%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $22.75
Upside: +119.78%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $10.07
Upside: +227.71%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $50.52
Upside: -50.51%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $13.58
Upside: +3.09%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.47
Upside: +111.64%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $68.98
Upside: -1.42%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $18.84
Upside: +6.16%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $487.43
Upside: -15.06%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $6.18
Upside: +45.63%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $7.61
Upside: +18.27%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $332.85
Upside: +58.33%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $85.45
Upside: +11.18%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $62.62
Upside: +27.75%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.98
Upside: +101.01%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $27.98
Upside: -39.24%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $8.08
Upside: +357.92%
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $72.75
Upside: -14.78%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $56.77
Upside: -1.36%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $32.29
Upside: -34.96%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $9.49
Upside: +226.66%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.11
Upside: +42.18%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $23.63
Upside: -61.91%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $8.18
Upside: +205.62%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.70
Upside: +133.77%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $7.49
Upside: +20.16%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.40
Upside: +4,992.59%